Abstract
The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to “generation” (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, secondgeneration formulations containing levonorgestrel, third-generation formulations containing desogestrel or gestodene, and oral contraceptives containing an estrogen and other progestagens (cyproterone or norgestimate) or a progestagen alone. The results of several studies was that the use of the older high-dose oral contraceptives increased the risk of cardiovascular disease by modifying the Low-density lipoprotein and High-Density lipoprotein cholesterol level, increasing triglyceride serum level, reducing glucose tolerance, raising blood pressure, and promoting clotting mechanisms. In this review we investigate the mechanism of the oral contraceptives and performed a risk assessment of every generation.
Keywords: Oral contraceptives, cardiovascular risk, generation, levonogestren, gestodene, desogestrel, Protrhombotic Effects, Contraceptives, cardiovascular dis-ease, thrombotic diseases, lynestrenol, norethindrone, levonorgestrel, estrogen, progestagens, cyproterone, norgestimate, progestagen alone, High-Density lipoprotein, triglyceride serum level, glucose tolerance, blood pressure, clotting mechanisms, cardial infarction, pulmonary embolism, venous thrombosis, atherosclerosis, sex hormones, monophasic gestodene, preparation, HDL, nandrolone derivatives, medroxyprogesterone acetate, diabetes mellitus, insulin, diuretics, antisympathetic agents, an-timineralocorticoid effect, fibrinolytic pathways, prothrombin, factor VII, factor VIII, factor X, fibrinogen, dislypidemia, coronary thrombosis, coronary heart disease
Current Pharmaceutical Design
Title: Protrhombotic Effects of Contraceptives
Volume: 16 Issue: 31
Author(s): Giovanni Fazio, Filippo Ferrara, Giuseppe Barbaro Gullotti Alessandro, Giovanni Ferrro, Giuseppina Novo and Salvatore Novo
Affiliation:
Keywords: Oral contraceptives, cardiovascular risk, generation, levonogestren, gestodene, desogestrel, Protrhombotic Effects, Contraceptives, cardiovascular dis-ease, thrombotic diseases, lynestrenol, norethindrone, levonorgestrel, estrogen, progestagens, cyproterone, norgestimate, progestagen alone, High-Density lipoprotein, triglyceride serum level, glucose tolerance, blood pressure, clotting mechanisms, cardial infarction, pulmonary embolism, venous thrombosis, atherosclerosis, sex hormones, monophasic gestodene, preparation, HDL, nandrolone derivatives, medroxyprogesterone acetate, diabetes mellitus, insulin, diuretics, antisympathetic agents, an-timineralocorticoid effect, fibrinolytic pathways, prothrombin, factor VII, factor VIII, factor X, fibrinogen, dislypidemia, coronary thrombosis, coronary heart disease
Abstract: The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to “generation” (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, secondgeneration formulations containing levonorgestrel, third-generation formulations containing desogestrel or gestodene, and oral contraceptives containing an estrogen and other progestagens (cyproterone or norgestimate) or a progestagen alone. The results of several studies was that the use of the older high-dose oral contraceptives increased the risk of cardiovascular disease by modifying the Low-density lipoprotein and High-Density lipoprotein cholesterol level, increasing triglyceride serum level, reducing glucose tolerance, raising blood pressure, and promoting clotting mechanisms. In this review we investigate the mechanism of the oral contraceptives and performed a risk assessment of every generation.
Export Options
About this article
Cite this article as:
Fazio Giovanni, Ferrara Filippo, Barbaro Gullotti Alessandro Giuseppe, Ferrro Giovanni, Novo Giuseppina and Novo Salvatore, Protrhombotic Effects of Contraceptives, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563374
DOI https://dx.doi.org/10.2174/138161210793563374 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Editorial [Hot Topic: Chemokine Inhibitors as Anti-Inflammatory Drugs (Executive Editor: David J. Grainger)]
Mini-Reviews in Medicinal Chemistry Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer
Reviews on Recent Clinical Trials Editorial [Hot topic: The Inflammation Paradigm in Cardiovascular Disease (Guest Editor: Guha Krishnaswamy)]
Cardiovascular & Hematological Disorders-Drug Targets Genome Wide Analysis of Chlamydia pneumoniae for Candidate Vaccine Development
Current Computer-Aided Drug Design New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews The Application of Natural Products in Cancer Therapy by Targeting Apoptosis Pathways
Current Drug Metabolism Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Brachial-Ankle Pulse Wave Velocity in the Measurement of Arterial Stiffness: Recent Evidence and Clinical Applications
Current Hypertension Reviews Editorial (Thematic Issue: The Current State of the Nation in Evaluating the Neonatal Brain Who? Why? How?)
Current Pediatric Reviews A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Current Pharmaceutical Design